secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001193125-24-271965
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024
---------------------------------------------------------------------

- Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.
- Annual base salary of $575,000; sign-on bonus of $325,000; target annual incentive bonus of 50% of salary.
- Granted incentive stock option for 160,000 shares and restricted stock units for 80,000 shares, both vesting over four years.
- Under the offer letter, severance includes 12 months base salary and COBRA premiums if terminated without cause.
- Appointment effective December 19, 2024; Emany will serve as principal financial officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312524271965/0001193125-24-271965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312524271965/d888673d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-271965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer